Exploring cancer metastasis prevention strategy: Interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Xie, Jingjing ^a   Dong, Haiyan ^a   Chen, Hongning ^a   Zhao, Rongli ^a   Sinko, Patrick J ^b   Shen, Weiyu ^a   Wang, Jichuang ^a   Lu, Yusheng ^a   Yang, Xiang ^a   Xie, Fangwei ^c   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b RUTGERS UNIVERSITY   (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Antibody conjugation; Cancer metastasis prevention; Cell adhesion; Circulating tumor cells; Multivalent binding

Indexed keywords

CELL ADHESION; CELL CULTURE; CELL MEMBRANES; CELLS; CYTOLOGY; DENDRIMERS; DISEASES; ENDOTHELIAL CELLS; NANOSTRUCTURED MATERIALS; PATHOLOGY; TUMORS;

ANTIBODY CONJUGATION; CANCER METASTASIS; CIRCULATING TUMOR CELLS; CONCENTRATION-DEPENDENT MANNERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MULTIVALENT BINDING; PREVENTION STRATEGIES; VASCULAR ENDOTHELIUM;

ANTIBODIES;

ANTIBODY CONJUGATE; ANTIMETASTATIC AGENT; DENDRIMER; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE SIALYL LEWIS X ANTIBODY POLYAMIDOAMINE DENDRIMER NANOMATERIAL CONJUGATE; FIBRONECTIN; NANOMATERIAL; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; PAMAM STARBURST; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CANCER CELL LINE; CELL ACTIVITY; CELL ADHESION; CELL SURFACE; CELL VIABILITY; CIRCULATING TUMOR CELL; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; METASTASIS; METASTASIS INHIBITION; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANTIBODIES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL ADHESION MOLECULES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOSTRUCTURES; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84924358169     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0072-x     Document Type: Article

References (51)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
2. Bach PB. Costs of cancer care: a view from the centers for Medicare and Medicaid services. J Clin Oncol. 2007;25:187-90.
3. Sethi N, Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer. 2011;11:735-48.
4. Klein CA. Cancer. The metastasis cascade. Science. 2008;321:1785-7.
5. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904.
6. Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823.
7. Kaiser J. Medicine. Cancer's circulation problem. Science. 2010;327:1072-4.
8. Plaks V, Koopman CD, Werb Z. Cancer. Circulating tumor cells. Science. 2013;341:1186-8.
9. Kling J. Beyond counting tumor cells. Nat Biotechnol. 2012;30:578-80.
10. Lu Y, Yu T, Liang H, Wang J, Xie J, Shao J, et al. Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade. Sci Rep. 2014;4:4344.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-91.
12. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci. 2005;42:155-96.
13. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398-406.
14. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2008;46:203-11.
15. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16:549-60.
16. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373:1681-92.
17. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002;94:291-7.
18. Wang S, Wang H, Jiao J, Chen KJ, Owens GE, Kamei KI, et al. Three Dimensional Nanostructured Substrates toward Efficient Capture of Circulating Tumor Cells. Angewandte Chemie. 2009;121:9132-5.
19. Wang S, Liu K, Liu J, Yu ZTF, Xu X, Zhao L, et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed. 2011;50:3084-8.
20. Myung JH, Gajjar KA, Saric J, Eddington DT, Hong S. Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells. Angew Chem Int Ed Engl. 2011;50:11769-72.
21. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol. 2013;8:881.
22. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol. 2013;8:735-41.
23. Wen CY, Wu LL, Zhang ZL, Liu YL, Wei SZ, Hu J, et al. Quick-response magnetic nanospheres for rapid, efficient capture and sensitive detection of circulating tumor cells. ACS Nano. 2014;8:941-9.
24. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469-78.
25. Balic M, Williams A, Lin H, Datar R, Cote RJ. Circulating tumor cells: from bench to bedside. Annu Rev Med. 2013;64:31-44.
26. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-8.
27. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349-61.
28. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-4.
29. Wang J, Chen J, Wan L, Shao J, Lu Y, Zhu Y, et al. Synthesis, Spectral Characterization, and In Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486). AAPS J. 2014;16:289-98.
30. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539-44.
31. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999;77:699-712.
32. Haier J, Nasralla M, Nicolson GL. Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg. 2000;231:11-24.
33. Matsushita Y, Hoff S, Nudelman E, Otaka M, Hakomori S, Ota D, et al. Metastatic behavior and cell surface properties of HT-29 human colon carcinoma variant cells selected for their differential expression of sialyl-dimeric Lex antigen. Clin Exp Metastasis. 1991;9:283-99.
34. Myung JH, Launiere CA, Eddington DT, Hong S. Enhanced tumor cell isolation by a biomimetic combination of E-selectin and anti-EpCAM: implications for the effective separation of circulating tumor cells (CTCs). Langmuir. 2010;26:8589-96.
35. Berg EL, Magnani J, Warnock RA, Robinson MK, Butcher EC. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun. 1992;184:1048-55.
36. Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J. 1999;18:1516-25.
37. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker Jr JR, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007;14:107-15.
38. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216-20.
39. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5:180ra148.
40. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005;48:3729-35.
41. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;19:1310-6.
42. Wang S, Wang H, Jiao J, Chen KJ, Owens GE, Kamei K, et al. Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl. 2009;48:8970-3.
43. Li W, Zhao H, Qian W, Li H, Zhang L, Ye Z, et al. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials. 2012;33:5349-62.
44. Thomas TP, Patri AK, Myc A, Myaing MT, Ye JY, Norris TB, et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules. 2004;5:2269-74.
45. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17:1109-15.
46. Xie J, Zhao R, Gu S, Dong H, Wang J, Lu Y, et al. The Architecture and Biological Function of Dual Antibody-Coated Dendrimers: Enhanced Control of Circulating Tumor cells and Their Hetero-Adhesion to Endothelial Cells for Metastasis Prevention. Theranostics. 2014;4:1250-63.
47. Shao J, Dai Y, Zhao W, Xie J, Xue J, Ye J, et al. Intracellular distribution and mechanisms of actions of photosensitizer Zinc(II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 2013;330:49-56.
48. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57:2215-37.
49. Malik AN, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener J, et al. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65:133-48.
50. Xie J, Zhao R, Lu Y, Wang J, Gu S, Jia L. Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29. In: Ministry of Science and Technology (MOST) and Chinese Academy of Sciences, The 450th Xiangshan-Science Conference and the 3th US-China Symposium on Cancer Nanotechnology and Nanomedicine. Beijing, China. 2012.
51. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-56.